Compare Rigetti Computing Inc (RGTI) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rigetti Computing Inc vs BIO-TECHNE Corp — how do they compare? Rigetti Computing Inc trades at $14.36 (market cap $4.72B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 2.4× Rigetti Computing Inc's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Rigetti Computing Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rigetti Computing Inc for 34 Days and BIO-TECHNE Corp for 63 Days on average.
| RGTI | TECH | |
|---|---|---|
Market Cap | $4.72B | $11.36B |
Volume | 17,136,381 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $56.34 | $72.61 |
52-Week Low | $12.90 | $43.31 |
Typical Hold Time | 34 Days | 63 Days |
Enterprise Value | $4.33B | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGTI trades at $14.59, down 3.82% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company shows minimal revenue of $7.09M in 2025 but faces substantial losses with a net income margin of -1,787.4%. Recent news highlights Rigetti's hybrid quantum-HPC strategy advancements and positive sector momentum from IonQ's developments.
Outlook remains speculative with high execution risks; analyst consensus is bullish (85.7% buy ratings) with a $21.67 price target, but persistent cash burn and negative profitability pose significant challenges. Investment opportunity hinges on quantum computing commercialization success against intense competition and funding needs.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
